ES2613400T3 - Método para mejorar la fagocitosis de células que exponen fosfatidilserina - Google Patents

Método para mejorar la fagocitosis de células que exponen fosfatidilserina Download PDF

Info

Publication number
ES2613400T3
ES2613400T3 ES10727986.1T ES10727986T ES2613400T3 ES 2613400 T3 ES2613400 T3 ES 2613400T3 ES 10727986 T ES10727986 T ES 10727986T ES 2613400 T3 ES2613400 T3 ES 2613400T3
Authority
ES
Spain
Prior art keywords
phosphatidylserine
cells exhibiting
improve phagocytosis
phagocytosis
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10727986.1T
Other languages
English (en)
Inventor
Christiaan Peter Maria Reutelingsperger
Peter Jozef Jacobus Moonen
Adriaan Thomas Vermaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MosaMedix BV
Original Assignee
MosaMedix BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MosaMedix BV filed Critical MosaMedix BV
Application granted granted Critical
Publication of ES2613400T3 publication Critical patent/ES2613400T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Variante de anexina A5, que comprende al menos una (1) y no más de veinte (20) secuencias de RGD en la cadena de anexina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES10727986.1T 2009-06-03 2010-06-03 Método para mejorar la fagocitosis de células que exponen fosfatidilserina Active ES2613400T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09161791 2009-06-03
EP09161791 2009-06-03
PCT/NL2010/050334 WO2010140886A1 (en) 2009-06-03 2010-06-03 Method for enhancing phagocytosis of phosphatidylserine-exposing cells

Publications (1)

Publication Number Publication Date
ES2613400T3 true ES2613400T3 (es) 2017-05-24

Family

ID=41009954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10727986.1T Active ES2613400T3 (es) 2009-06-03 2010-06-03 Método para mejorar la fagocitosis de células que exponen fosfatidilserina

Country Status (9)

Country Link
US (1) US8658768B2 (es)
EP (1) EP2437773B1 (es)
JP (2) JP2012528855A (es)
AU (1) AU2010254681B2 (es)
CA (1) CA2764029C (es)
DK (1) DK2437773T3 (es)
ES (1) ES2613400T3 (es)
NZ (1) NZ596862A (es)
WO (1) WO2010140886A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6290187B2 (ja) * 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
EP3292140B1 (en) * 2015-05-05 2022-04-20 Rubicon Biotechnology LLC Cancer immunotherapeutic
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
KR101857246B1 (ko) 2015-10-28 2018-05-11 광주과학기술원 인공 사멸세포 수용체 및 이의 용도
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2019058374A1 (en) * 2017-09-19 2019-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. N-METHYLATED CYCLIC PEPTIDES AND PRODRUGS THEREOF
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181099C (zh) * 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB
WO2005019429A2 (en) * 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
CA2633033C (en) * 2005-12-12 2016-11-22 Mosamedix B.V. Annexin derivatives suitable for pretargeting in therapy and diagnosis
KR100968839B1 (ko) * 2008-02-25 2010-07-09 경북대학교 산학협력단 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
KR101519496B1 (ko) * 2008-12-31 2015-05-13 에스케이케미칼 주식회사 양이온 교환 제올라이트 촉매 및 이를 이용한 트랜스 요오드화 반응을 통한 모노-요오드 벤젠의 제조 방법

Also Published As

Publication number Publication date
EP2437773B1 (en) 2016-11-16
US8658768B2 (en) 2014-02-25
CA2764029C (en) 2019-10-29
US20120094895A1 (en) 2012-04-19
JP2016040283A (ja) 2016-03-24
EP2437773A1 (en) 2012-04-11
AU2010254681B2 (en) 2016-08-11
WO2010140886A1 (en) 2010-12-09
DK2437773T3 (en) 2017-02-06
NZ596862A (en) 2013-07-26
JP2012528855A (ja) 2012-11-15
AU2010254681A1 (en) 2011-12-15
CA2764029A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
ES2613400T3 (es) Método para mejorar la fagocitosis de células que exponen fosfatidilserina
ES2565308T3 (es) Dispositivo poligonal generador de aerosol
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2629749T3 (es) Inmunidad tumoral
AR077541A1 (es) Aditamento para maquina cosechadora
ES2616049T3 (es) Mejora de la función renal con composiciones que contienen quercetina
ES2637421T3 (es) Composiciones tópicas que comprenden variantes de pliegue-OB
JP2010223903A5 (es)
ES2509740T3 (es) Composición cuasi-azeotrópica de 2,3-dicloro-3,3-difluoropropeno (HCFO-1232xf) y fluoruro de hidrógeno (HF)
ES2523889T3 (es) Recubrimiento reducido de azúcar que incluye almidón resistente y su método de fabricación
ES2508165T3 (es) Lactoferrina y sustancia blanca
ES2634034T3 (es) Composiciones nutricionales con copos de fruta que contienen ácido docosahexenoico
CR20150310A (es) Solución para preservar conductos vasculares
ES2501595T3 (es) Plancha litográfica de aluminio
ES2568945T3 (es) Procedimiento para imponer un esquema de color dinámico en la luz de una unidad de iluminación
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
CO6331392A2 (es) Estructura impresa para realizar productos varios, contenedores para productos, etiquetas y similares
ES2619837T3 (es) Composición líquida estable de sulfato de condroitina y glucosamina
ES2583004T3 (es) Olleya marilimosa y su uso en un método para la preparación de una composición que contiene zeaxantina
ES2561813T3 (es) Aplicación tópica de nimesulida y tiocolchicósido
ECSP10010552A (es) Asociacion de LA dronedarona con al menos un diuretico, su aplicacion en terapeutica
ES2526968T3 (es) Una composición agrícola, método para su producción y usos en el tratamiento de cultivos
ES2563287T3 (es) Un proceso de fabricación de zeranol
ES2524894T3 (es) Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe
ES2526816A1 (es) Composiciones para el tratamiento del daño hepático